NextCell Pharma AB (FRA:65G) YoY EBITDA Growth : 65.38% (As of Feb. 2025)

View and export this data going back to 2020. Start your Free Trial

What is NextCell Pharma AB YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. NextCell Pharma AB's YoY EBITDA Growth for the quarter that ended in Feb. 2025 was 65.38%.

NextCell Pharma AB's EBITDA per Share for the three months ended in Feb. 2025 was €-0.01.

NextCell Pharma AB YoY EBITDA Growth Historical Data

The historical data trend for NextCell Pharma AB's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextCell Pharma AB YoY EBITDA Growth Chart

NextCell Pharma AB Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Aug24

YoY EBITDA Growth

Get a 7-Day Free Trial

10.53

-5.88

-37.04

-4.05

36.36

NextCell Pharma AB Quarterly Data
	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24	Feb25
YoY EBITDA Growth	Get a 7-Day Free Trial															-13.04	21.43	6.25	62.50	65.38

NextCell Pharma AB YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

NextCell Pharma AB's YoY EBITDA Growth for the fiscal year that ended in Aug. 2024 is calculated as:

	YoY EBITDA Growth (A: Aug. 2024 )
=	(EBITDA per Share (A: Aug. 2024 )	-	EBITDA per Share (A: Aug. 2023 ))	/	\| EBITDA per Share (A: Aug. 2023 ) \|
=	(-0.049	-	-0.077)	/	\| -0.077 \|
=	36.36 %

NextCell Pharma AB's YoY EBITDA Growth for the quarter that ended in Feb. 2025 is calculated as:

	YoY EBITDA Growth (Q: Feb. 2025 )
=	(EBITDA per Share (Q: Feb. 2025 )	-	EBITDA per Share (Q: Feb. 2024 ))	/	\| EBITDA per Share (Q: Feb. 2024 )) \|
=	(-0.009	-	-0.026)	/	\| -0.026 \|
=	65.38 %

NextCell Pharma AB YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of NextCell Pharma AB's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

NextCell Pharma AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NextCell Pharma AB (FRA:65G) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

NXTCL:Sweden

Address

Karolinska Institutet Science Park, Halsovagen 7, Huddinge, SWE, 14157

Website

http://www.nextcellpharma.com

NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.

NextCell Pharma AB Headlines

No Headlines